U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Indoco Remedies Limited - 575313 - 05/01/2023
  1. Warning Letters

CLOSEOUT LETTER

Indoco Remedies Limited MARCS-CMS 575313 —

Product:
Drugs
Recipient:
Recipient Name
Suresh G. Kare
Recipient Title
Chairman
Indoco Remedies Limited

Indoco House, 166 CST Road
Mumbai 400098
India

Issuing Office:
Center for Drug Evaluation and Research | CDER

United States

Dear Mrs. Panandikar:

The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 320-19-29 dated July 9, 2019.

Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority.

The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.


Sincerely,
/S/
Joseph Lambert, Pharm.D.
Compliance Officer
Division of Drug Quality I

Back to Top